Comentario editorial. La importancia de los trastornos hipertensivos del embarazo como factor de riesgo cardiovascular en las mujeres

  1. Guzmán Martínez, Gabriela 123
  2. Contreras Mármol, Helena 1
  3. Castro Conde, Almudena 1
  1. 1 Atrys Health, Madrid
  2. 2 Instituto de Investigación Sanitaria del Hospital Universitario La Paz
    info

    Instituto de Investigación Sanitaria del Hospital Universitario La Paz

    Madrid, España

    ROR https://ror.org/017bynh47

  3. 3 Universidad Europea de Madrid
    info

    Universidad Europea de Madrid

    Madrid, España

    ROR https://ror.org/04dp46240

Zugehörigkeit anzeigen +
Zeitschrift:
JACC. Edición en español

Datum der Publikation: 2022

Ausgabe: 01

Nummer: 26

Seiten: 46-48

Art: Artikel

GOOGLE SCHOLAR lock_openOpen Access editor

Bibliographische Referenzen

  • 1. Anna C. O ́Kelly, Erin D, Michos, et al. Pregnancy and Reproductive Risk Factors for Cardiovascular Disease in Women. Circulation Research. 2022, 130: 652-672.
  • 2. Anandita Agarwala, MD, Erin D. Michos, MD, et al. the Use of Sex-Specific Factors in the Assess-ment of Women ́s Cardiovascular Risk. Circulation. 2020, 141: 592-599.
  • 3. Kattah A, Garovic V. The Management of Hyper-tension in Pregnancy. Adv Chorinc Kidney Dis. 2013, 20 (3): 229-239.
  • 4. Benschop L, Duvekot J, Roeters van Lennep J, et al. Future risk of cardiovascular disease risk factors and events in women after a hypertensive disorder of pregnancy. Heart. 2019, 105: 1273-1278.
  • 5. Hauspurg A, Ying W, Hubel C, et al. Adverse pregnancy outcomes and future maternal cardio-vascular disease. Clinical Cardiology. 2018, 41: 239-246.
  • 6. Parikh N, Gonzalez JM, Anderson C, et al. Adverse Pregnancy Outcomes and Cardiovascular Disease Risk: Unique Opportunities for Cardiovas-cular Disease Prevention in Women. Circulation. 2021, 143: 902-916.
  • 7. Lane-Cordova A, Khan S, Grobman W, et al. Long-Term Cardiovascular Risks Associated With Adverse Pregnancy Outcomes. Journal of the American College of Cardiology. 2019, 73 (16): 2106-2016.
  • 8. Saeed A, Kampangkaewm J, et al. Prevention of Cardiovascular Disease in Women. Methodist Debakey Cardiovasc Journal. 2017;13:185-192.
  • 9. Stuart JJ, Tanz LJ, Rimm EB, et al. Cardiovascu-lar risk factors mediate the long-term maternal risk associated with hypertensive disorders of pregnancy. J Am Coll Cardiol. 2022; 79:1901-1913.
  • 10. Grundy SM, Stone NJ, Bailey AL, et al. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA guideline on the management of blood cholesterol: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation. 2019, 139: 1082-1143.
  • 11. Arnett DK, Blumenthal RS, Albert MA, et al. 2019 ACC/AHA guideline on the primary prevention of cardiovascular disease. Circulation. 2019, 140: 596-646.
  • 12. Regitz-Zagrosek V, Roos-Hesselink JW, Bauer-sachs J, et al. 2018 ESC Guidelines for the management of cardiovascular diseases during pregnancy. European Heart Journal. 2018, 39: 3165-3241.
  • 13. Visseren F, Mach F, Smulders YM, et al. 2021 ESC Guidelines on cardiovascular disease prevention in clinical practice. European Heart Journal. 2021, 42: 3227-3337.
  • 14. Stuebe AM, Auguste TC, Gulati M. Optimizing postpartum care. ACOG Committee Opinion No. 736. American College of Obstetricians and Gynecologists. ACOG Presidential Task Force. Obstet Gynecol 2018, 131: 140-150.
  • 15. Brown HL, Warner JJ, Gianos E, et al. Promoting risk identification and reduction of cardiovascular disease in women through collaboration with obstetricians and gynecologists: a Presidential Advisory from the American Heart Association and the American College of Obstetricians and Gynecologists. Circulation 2018, 137: 843-852.
  • 16. Castro Conde A, et al. Recomendaciones de seguimiento a partir del cuarto trimestre de mujeres con complicaciones vasculares y metabólicas durante el embarazo. Documento de consenso de la SEC, SEMERGEN, semFYC y SEGO. REC CardioClinics. 2019.